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Surgical margin status in cancer surgery represents an important oncologic parameter affecting overall 
prognosis. The risk of disease recurrence is minimized and survival often prolonged if margin-negative 
resection can be accomplished during cancer surgery. Unfortunately, negative margins are not always 
surgically achievable due to tumor invasion into adjacent tissues or involvement of critical vasculature. 
Herein, we present a novel intra-operative device created to facilitate a uniform and mild heating profile 
to cause hyperthermic destruction of vessel-encasing tumors while safeguarding the encased vessel. 
We use pancreatic ductal adenocarcinoma as an in vitro and an in vivo cancer model for these studies 
as it is a representative model of a tumor that commonly involves major mesenteric vessels. In vitro 
data suggests that mild hyperthermia (41–46 °C for ten minutes) is an optimal thermal dose to induce 
high levels of cancer cell death, alter cancer cell’s proteomic profiles and eliminate cancer stem cells 
while preserving non-malignant cells. In vivo and in silico data supports the well-known phenomena 
of a vascular heat sink effect that causes high temperature differentials through tissues undergoing 
hyperthermia, however temperatures can be predicted and used as a tool for the surgeon to adjust 
thermal doses delivered for various tumor margins.
Surgical margin status in cancer surgery represents an important factor affecting the overall prognosis of the 
patient. The risk of adverse patient outcomes and surgical-margins recurrence is usually greatly minimized if the 
surgeon is able to achieve a grossly and pathologically negative margin during cancer surgery1. Unfortunately, 
there are many cancers for which negative margins cannot be surgically achieved at the time of diagnosis due to 
various factors, including tumor involvement of critical anatomical structures2–12. Such locally advanced invasion 
may constitute a contraindication to surgery, and if surgery is attempted, patients stand at high risk for early 
tumor recurrence and further disease progression.
Tumor involvement of major vasculature represents a perplexing problem that increases both surgical and 
oncologic risks for poor outcomes, with significant likelihood of a positive surgical margin2–12. This is seen in 
a wide range of cancers including, but not limited to, paragangliomas5, hepatocellular carcinoma13, pancreatic 
ductal adenocarcinoma (PDAC)14, 15, perihilar cholangiocarcinoma2, 3, neuroblastoma6, leiomyosarcoma8, ret-
roperitoneal sarcoma16 and Kaposiform hemangioendothelioma8. Venous involvement can sometimes, but not 
always, be addressed by surgical resection and reconstruction of the vessels affected, such as in the case of hepa-
tocellular carcinoma, which has invaded the portal vein, hepatic vein or inferior vena cava7. However, these 
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procedures come with an increased risk to the patient13. PDAC14, 15, neuroblastoma6, Kaposiform hemangio-
endothelioma,8 gastrointestinal neuroendocrine tumors17, and metastatic squamous cell carcinoma18 represent 
some cancers that commonly display arterial involvement. Arterial resection and reconstruction represent an 
even greater risk and often represent a contraindication to surgery.
The work herein uses in vitro and in vivo models to investigate the use of applied hyperthermia to 
intra-operatively treat patients when a positive surgical margin is enountered. We use PDAC as a cancer model 
for these studies as PDAC commonly displays involvement with major mesenteric vessels, in particular the supe-
rior mesenteric artery (SMA)14, 15 (Figure S1A–C). Our method for applying hyperthermia was through a novel 
prototype device named the ‘CorleyWare’ device (CWD). The CWD is a resistive heating device designed to facil-
itate a uniform heating profile around the tumor and is based on the phenomenon of cancer cells being especially 
sensitive to hyperthermia19. Unlike conventional hyperthermia intraoperative techniques, such as RF ablation 
(standard RF ablation thermal dose is 70 °C for 5 minutes20) that are associated with coagulative necrosis and 
inflammation to healthy periablative tissues20, the CWD aims to expose cancer tissue to more mild hyperthermia 
over the tens of minutes timescale (41–46 °C for 10 minutes) to eliminate cancer progression after surgery whilst 
preserving healthy adjacent tissues. A schematic overview of the concept is highlighted in Figure S1D and the two 
versions of the device are depicted in Figure S2. Furthermore, we believe this form of intra-operative hyperther-
mia treatment may target a dangerous sub-population of cancer cells, namely cancer stem cells (CSCs)21, which 
are implicated in tumor resistance and recurrence. CSCs are defined as cells within a tumor that can self-renew 
and drive tumorigenesis. It is hypothesized that CSCs may generate tumors through stem cell processes of 
self-renewal and differentiation into multiple cell types. Although some studies have shown that certain agents, 
such as siRNA, can somewhat reduce CSCs populations22, 23, there are currently no approved treatments that spe-
cifically target CSCs, which contributes to slow advancements in patient outcome over the last four decades when 
an intravenous cytotoxic or biological agent approach has been taken.
In summary, we provide insight into the effects of mild hyperthermia on cancer, stromal and endothelial cells 
in vitro 2D monolayer settings, including CSCs renewability potential. We determine hyperthermia gradients in 
tumor tissue due to localized heating and subsequent intra-tumoral cellular damage due to hyperthermia in vivo 
murine and swine models. Finally, we validate our results with a simple mathematical model of hyperthermia 
dissipation in tumor encased SMA tissues when exposed to CWD heating.
Results and Discussion
The effect of hyperthermia on PDAC, Pancreatic stellate cells and Endothelial cells. In-vitro 
investigation was carried out to establish an approximate thermal dose that eliminated PDAC cell lines while 
minimizing the effects on healthy tissues. The CWD will be required to operate within an optimal thermal dose, 
where there is sufficient hyperthermia to enable tumor destruction while simultaneously limiting damage to 
healthy vascular tissue, as local thrombosis may occur leading to ischemia in the tissues downstream of the SMA 
and cause major complications in the patient. At the same time, weakening of the arterial wall can cause pseu-
doaneurysmal dilation and rupture, an equally catastrophic outcome. Initial in-vitro studies will allow the deter-
mination of thermal doses needed for the CWD application. The cell death induced by thermal doses of 42 °C, 
44 °C and 46 °C for 10 minutes after an initial thermal increase from 35 °C which took 5 minutes were investigated 
(Fig. 1A).
The benefit of in-vitro population-wide high throughput cytotoxicity studies have previously been described24. 
This analysis was performed using numerous relevant cell lines to the PDAC-SMA environment and indicated 
that a thermal dose of 44–46 °C for 10 min would induce the greatest cytotoxicity in cancer cell lines while min-
imizing the effects seen in normal vascular endothelial cell lines (Fig. 1A–C). Activated pancreatic stellate cells 
(PSCs) were also included in the analysis as these cells are known to drive the dense stromal reaction often 
found in human pancreatic tumors25 and have been linked to tumor progression26–30. Other hyperthermia 
effects on PDAC cells, such as cytoplasmic retraction and alterations in cell metabolism have also previously 
been reported31. Importantly, we have found that hyperthermia pretreatment means an increase in susceptibility 
of cancer cells to chemotherapy (Fig. 1D). This is a clinically relevant finding as intraoperative hyperthermia 
administration via the CWD may induce the positive margin left after surgery to be more chemo-sensitive in 
later patient chemotherapy regimens. However, it is not currently known how long increases in susceptibility to 
chemotherapy due to hyperthermia pretreatment remain. Although these studies do not recapitulate the true bio-
logical environment, which includes arterial blood flow and the extra-cellular environment, they do provide some 
insight into the thermal dose required for greatest differential in cell death between malignant and healthy cells.
In addition to the treatment of the bulk of the tumor remaining after surgery, we believe hyperthermia admin-
istered to PDAC cells encompassing the outer surface of the SMA will target specific cell populations that are 
particularly relevant to tumor drug resistance and regrowth, which include CSCs. Water bath heating of several 
cancer cell lines destroyed the viability and renewability potential of CSCs within these cancer cell populations 
(Fig. 2), as measured via tumor sphere forming assay and surface marker CD24 and CD44 analysis. The expres-
sion of CD24, CD44 surface markers have previously been associated with cancer cell stem-ness32–34, however the 
tumor sphere formation assay was chosen as the primary determination of CSC over surface marker expression 
in this study due to the potential of surface marker membrane binding sites being affected when exposed to 
hyperthermia and thus may lower their predictive power of cancer stem-ness. We have recently reported that 
hyperthermia in these ranges (37–46 °C) alter PDAC cells’ membrane and affects their ability to adhere to the 
cell culture substrate35. The tumor sphere formation assay is a functional test that determines the CSC behavior 
of the cell population despite what markers the cells may express on their membrane. This being said, we have 
included CD24 and CD44 surface membrane expression in one cancer cell line (PANC-1) and showed that CSC 
marker expression declined as thermal dose is increased (Fig. 2). Sphere formation 14-days after heat treatment 
was quantified to rule out the possibility of heat-treated CSCs remaining dormant for a length of time, only to 
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develop at a later date, which prompts recurrence of a tumor. The tumor formation assay (Fig. 2) indicates that 
a single heat treatment (41 °C for 10 mins) eliminates (>95%) of CSCs in PDAC cell populations, as it abolished 
the tumor sphere forming ability of the treated cells in-vitro. This effect was present in a wide range of differ-
ent PDAC cell lines; AsPc-1, PANC-1, MIA-PaCa-2 as well as in non-malignant pancreatic stellate cells (PSCs). 
PSCs were included in this set of experiments as recent studies have alluded to PSCs playing an important role 
in promoting local growth of PDAC, facilitating regional and distant spread of PDAC cells26, 27, aiding PDAC 
immune-evasion28, 29 and facilitation of a CSC niche in PDAC, all of which have major impact on the progression 
of PDAC and play a role in its high recurrence rate. Alterations to PSCs may also play a role in halting PDAC 
tumor renewal after CWD treatment. Although responses observed were thermal dose dependent, effects were 
observed even at the lowest thermal doses.
All PDAC cell lines and PSCs showed a complete disruption of CSC viability when given a thermal dose of 
46 °C for 10 minutes (Fig. 2). This indicates that collateral thermal damage to healthy tissues during heat treat-
ment can be minimized as 46 °C for 10 minutes is not classed as ablation which causes inflammation and damage 
to healthy tissues surrounding the diseased loci.
We further investigated the effects of hyperthermia on PDAC cells by exploring the changes in protein expres-
sion induced by mild hyperthermia (41 °C for 10 mins) via the reverse-phase protein array (RPPA). The antibody 
panel used for the RPPA included 212 proteins covering major cellular signaling pathways involved in numerous 
Figure 1. Heating and cell viability. (A) Morphological changes in HUVEC cells 24 h after hyperthermia (44 °C 
for 10 min) are not observed via SEM. (B) Percentage cell death of various cell lines of the pancreatic cancer 
microenvironment at 0 h after heat treatment at various temperatures (C) % cell death of various cell lines of 
the PDAC microenvironment 24 h after heat treatment at various temperatures (D) Viability of PANC-1 cells 
48 h after gemcitabine exposure and hyperthermia pre-treatment (Thermal treatment consisted of 10 minute 
duration at desired temperatures (i.e. 37, 42, 44 and 46 °C, error bars represent standard deviation, experiment 
performed in triplicate).
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aspects of cancer development and progression. The Student’s t-test was used to identify significantly differenti-
ated levels of total or phosphoproteins with p-value < 0.05 and fold-change >1.25 (or <1/1.25). We discovered 
that mild hyperthermia induced the expression of 23 up-regulated proteins and 44 down-regulated proteins when 
compared to untreated cells (Figure S3A, Table S1). Further analysis using Ingenuity pathways analysis identified 
several significantly (Z-score >1 or <−1) associated canonical pathways, most of which were down-regulated 
after hyperthermia treatment (Figure S3B).
All hyperthermia-altered proteins are listed in Table S1, however full discussion on all altered proteins in the 
hyperthermia treated cells is outside the scope of this manuscript. Briefly, canonical pathway analysis, which 
correlates altered protein expression with specific pathways and disease states and bio-functionality highlighted 
Figure 2. Hyperthermia decreases renewability of PDAC stem cells. (A) Brightfield image of PANC-1 cancer 
cells before treatment (left) and with heat treatment (46 °C for 10 minutes) (right) (B–F) the number of viable 
PDAC and PSCs spheres formed at 14 days after water bath heat treatment. G-H) CD24+ and CD44 CSC 
surface marker expression in PANC-1 cells after 37–46 °C hyperthermia exposure for 10 minutes.
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many signaling pathways altered in hyperthermia treated cells (Figure S3B). Specifically, the most significant 
down-regulated pathways were pathways related to epidermal growth factor receptor (EGF), mitogen-activated 
protein kinase (MAPK), adenosine monophosphate-activated protein kinase (AMPK) and interleukin-8 (IL-8) 
signaling. The EGFR belongs to the ErbB group of receptor tyrosine kinases and previous studies have shown 
that it is involved in the pathogenesis and progression of various types of carcinoma36. The MAPK pathways are 
activated by various intra- and extra-cellular stimuli, such as cytokines, hormones, and cellular stressors such as 
endoplasmic reticulum stress and oxidative stress. MAPK pathways control a variety of cellular functions that 
include proliferation, differentiation, survival, and cell death. Deviation from the precise regulation of MAPK 
signaling pathways has been shown to play a role in the progression of various cancers37 and has been associ-
ated in immune evasion38 of melanoma cells. AMPK is a key energy sensor which is activated by increases in 
adenosine monophosphate (AMP)/adenosine triphosphate (ATP) ratio and/or adenosine diphosphate (ADP)/
ATP ratio, and increases various metabolic pathways including mitochondrial biogenesis, fatty acid oxidation 
and glucose transport39. The activation of AMPK-autophagy pathway plays a role in drug resistance in colorectal 
cancer39. IL-8 is a chemo-attractant cytokine produced by various tissues40 and its up-regulation is implicated in 
pancreatic cancer invasion and metastasis41. p53 signaling was shown to be the most significantly up-regulated 
canonical pathway. The p53 homolog is crucial in multicellular organisms, where it prevents cancer formation, 
thus, functions as a tumor suppressor42.
To summarize, our in vitro data determines that a more mild hyperthermia, in the range of 46 °C in for 10 min-
utes is sufficient to cause cancer cell cytotoxicity, induce alterations in protein expression associated in various 
signaling pathways in PDAC cells and destroys CSC renewability potential.
In vivo hyperthermia differential. Investigation into the heating kinetics of PDAC and vascular tissue 
provided valuable information to enable optimal thermal dose administration to the cancer layer whilst simul-
taneously minimizing unwanted damage to the intima and lumen of the SMA. CWD testing on ex-vivo and 
deceased in-situ porcine models determined the heat differential in ‘dry’ tissue, where blood flow is removed as 
a variable.
The porcine aorta was used in the ex-vivo experiments as it represents a good comparison to the human SMA 
due to a more consistent size. Without blood flow present, which is expected to increase the heat differential 
between outside surface and lumen of artery even further, there is a constant differential of approximately 2 °C 
(Figure S4) which is primarily due to the wall of the aorta.
In addition to a healthy aorta, we investigated the heat differential through an orthotopic murine PDAC tumor 
sample. The positive margin involved with the SMA will undoubtedly deviate from patient to patient, however 
we choose to investigate the heat differential across a 2 mm distance, as 2 mm represents a fairly realistic positive 
margin after surgery. An optical probe was place on the tumor boundary (Figure S4A) and another approximately 
2 mm inside an ex vivo mouse orthotopic PDAC tumor (Figure S4B).
The quantification of heat differentials through artery and PDAC tumor tissue is essential for optimizing the 
thermal dose needed to destroy cancer cells throughout a 2–4 mm PDAC tumor positive margin while preserving 
the endothelium and smooth muscle found in the underlying artery. Failure to give an adequate thermal dose will 
mean low efficacy of the treatment whilst a thermal dose which is too high will cause damage to arterial tissues 
and could result in downstream ischemia in the gut or blood clotting, which are both dangerous to the patient and 
can be fatal. Figure S5A and B depict the experimental set-up and Figure S5D–F indicates the temperatures 2 mm 
inside an orthotopically grown PDAC tumor when the tumor-CWD boundary is heated to various temperatures. 
We find that a tumor-CWD boundary of 52 °C is necessary to achieve the proposed temperature gradient of at 
least 46 °C through a 2 mm thick tumor tissue.
We went on to investigate the heat differential in PDAC in a live mouse where blood flow was present within 
the PDAC tumor (Fig. 3). Once again, we placed an optical temperature probe on the surface of the tumor and 
inserted a second probe approximately 2 mm intra-tumorally. We also placed a rectal probe to record body core 
temperature to ensure the mouse was not subject to total body hyperthermia. As expected, we found the heat 
differential was increased (between 10–15 °C) when compared to the ex vivo tumor sample. The differentials 
seen here are substantial considering the tumor in this experiment is only fed by disorganized and small tortuous 
tumor vessels in a small animal model. Clinically, these differentials are underestimations when compared to the 
tumor under hyperthermia in PDAC human patients as the tumor tissue in the clinical setting will be proximal 
to a much higher blood flow from the SMA that is approximately 7 mm in diameter. Nevertheless, histological 
analysis of various tumor samples revealed excessive cell death between the border of the treated tumor and 2 mm 
inside the tumor as indicated by Cl-PARP histology staining (Fig. 3F,G). Collagenous extra cellular proteins, as 
indicated by picro sirius staining, did not show any significant alteration.
Effect of the blood heat sink on heating dynamics. Experiments regarding testing heating dynamics 
of the CWD-SMA system until now have been performed in ex-vivo SMA samples, in deceased in-situ porcine 
models or in in vivo murine models, which do not recapitulate the heavy pulsatile blood flow that would be pres-
ent in human patients. A shortcoming of current various heating techniques in cancer therapy devices, such as 
radiofrequency ablation, is the limited performance adjacent to large blood vessels (diameter >3 mm). When the 
heating occurs near large vessels, the blood flow dissipates thermal energy away from the target tissue43. This is a 
heat sink effect that can change both the shape and maximum volume that can be treated. In fact, the distance of 
the blood vessels from the tumor determines the location of the maximal tissue temperature. As a result, tumors 
in the vicinities of large vessels are associated with high recurrence rates from incomplete thermal desctruction44. 
We believe we can mitigate these challenges by investigating the heating dynamics with specific consideration of 
blood flow characteristics along with the size of the patient and their SMA, and the thickness of the remaining 
positive margin enables a powerful tool to achieve insight into the heat dynamics within a given system. These 
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details, in theory, will enable the surgeon to tune the CWD temperature to personalize the thermal dose given to a 
particular patient. However, we hypothesize that blood flow through the SMA lumen will be advantageous in this 
instance as it will increase heat differential between outside cancer layer and inside healthy vasculature. To explore 
this possibility we investigated the heating dynamics of the CWD when placed around the femoral artery (FA) in 
Figure 3. Tumor heat differential and cell death in in vivo murine PDAC model. (A) PDAC tumor is positioned 
for heat treatment (B) the heating device is placed onto the tumor (C) heat differential between tumor boundary 
and tumor core (mouse body core temperature is also displayed) (Black arrow depicts the point at which 46 °C 
in the tumor core was reached and the red arrow indicates the end of the treatment time when the device was 
removed). (D) and (E) tumor after treatment (yellow scale bar = 2 cm, and yellow arrow represents heated side 
of tumor) (F) and (G) Row of histological cross-sectional micrographs of tumors treated with hyperthermia 
as described by Fig. 3A–E (from left to right, (H&E), picro Sirius and Cl-PARP histology stains, red arrows 
indicate heated surface, black scale bars = 2 mm).
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a live swine model to perform CWD testing when a high pulsatile blood flow is present and obtain temperature 
profiles of vessel interfaces as a function of time (Fig. 4). The FA was chosen for testing, as it is superficial for 
easier surgical access and also similar in size to the SMA in humans and is intended to provide proof of principle 
regarding the blood flow heat sink effect. An optic temperature probe was secured onto the outside surface of the 
artery, and a second probe was inserted into the lumen of the artery before the CWD was placed around the artery 
(Fig. 4A) and current was passed through the device to produce a localized thermal dose. This test confirmed the 
CWD could be accurately fitted to a vessel without major occlusion, which is particularly relevant because SMA 
occlusion can result in a downstream ischemic insult in the intestine45. The differential between the inside lumen 
and outside surface of the FA (artery wall is approximately 0.5–1 mm thick) when blood is flowing is ~1.5–2 °C 
when outside surface was heated to 46 °C (Fig. 4C). The vessel after heating showed minimal signs of thermal 
damage (Fig. 4B).
To complement our experimental findings, we developed a simple simulation to provide some information 
of the heating differentials seen through the whole tumor-vessel system (Fig. 4D,E). This simple simulation of 
the CWD utilized the Pennes bioheat transfer equation46 and used Sim4Life software (ZMT Zurich MedTech 
AG, Zurich, Switzerland)47. The model for all simulations consisted of a cylindrical blood vessel (inner diameter 
10 mm, with 1 mm vessel walls), partially enclosed by a cylindrical section of pancreatic tumor tissue of thickness 
between 1–10 mm. Our aim was to heat the full thickness of the tumor tissue to at least 46 °C while limiting the 
temperature at the artery interface. The simulation displayed large thermal differentials even through small thick-
nesses of tissues. For instance, to achieve a temperature of at least 46 °C with a tumor tissue layer of only 1 mm, the 
CWD would have to heat the tumor boundary to at least 52 °C (Fig. 4D). For a 10 mm tumor layer, CWD tumor 
boundary temperatures in excess of 80 °C only achieved 46 °C through half of the tumor tissue (Fig. 4E).
The aim of the CWD is to deliver a thermal dose intra-operatively to the outside tumor layer that is sufficient 
enough to destroy cancer cells and to delay or eliminate recurrence of the tumor. It is essential that at the same 
time the prevention of significant damage to the underlying artery is achieved and hence the function of down-
stream tissues and organs can be maintained. Additionally, thrombosis or weakening of the heated artery needs to 
be avoided. The arterial viability following hyperthermia treatment was evaluated by histology following the exci-
sion of the FA straight after treatment. Figure 5A,B and C shows a planar view of an untreated, a CWD-treated 
FA and a FA that has undergone extensive heating, respectively, (55 °C for 10 mins) to act as a positive control. No 
obvious pathological features exist in the tunica intima, media or adventitia immediately after CWD treatment at 
this thermal dose. Alternatively, the positive control shows a ruffled endothelium and shrinkage in the width of 
the tunica media. SEM imaging performed on the tunica intima layer of the vessel showed no observable pathol-
ogy (Fig. 5D,E).
The data thus far has not considered any delayed onset of pathological conditions relating SMA hyperther-
mia treatment, such as structural compromise of the vessel, ruffled endothelial layers or downstream abdomi-
nal ischemia. For this consideration, we exposed the anterior mesenteric artery (AMA, which is the quadruped 
analogue of SMA) of a live pig to 41 °C for 10 minutes and a necropsy was scheduled for 48 h after treatment. 
An inspection of the AMA, surrounding tissues, including the proximal vessels and the small intestines found 
no obvious damage to any of the organs immediately after hyperthermia treatment. The animal was monitored 
throughout the day and into the evening by veterinary staff. A heat lamp was provided to aid in thermoregula-
tion after surgery. Postoperative antibiotics were administered (5 mg/kg enrofloxacin IV twice, 5 mg/kg ceftiofur 
IM once, 1 gram cefazolin IV once, 1 L of lactated ringers saline IV twice, 60 mL D5W IV once) in the time 
between surgery and necropsy. At the 48 h time-point, the animal was euthanized after sedation. The animal was 
euthanized after 48 h because it showed signs of distress and abdominal discomfort, which on gross pathologic 
examination was due to an inadvertently retained laparotomy sponge at the initial surgical procedure. There was 
post-operative peritonitis from the foreign body but there was no observed evidence of ischemic necrosis in the 
stomach, small intestine, or large intestine. The AMA appeared patent with no observed thrombosis or dilation; 
all bowel appeared viable without evidence of vascular compromise (Figure S6, Fig. 5). There was an extensive 
foreign body reaction and localized fibrinopurulent peritonitis with an accumulation of a large amount of ascitic 
fluid in the peritoneal cavity as a result of the extensive manipulation of the abdominal organs and the dissection 
and isolation of the AMA, as well as fibrinous adhesions between loops of intestine commensurate with the recent 
laparotomy and reaction to the foreign body.
Histological analysis revealed acute marked fibrinopurulent inflammation and coagulative necrosis around 
the isolated treated segment of the artery that is consistent with a surgical procedure that reportedly involved 
extensive manipulation of the abdominal viscera (Fig. 5). The isolated segment of the artery consisted of a cen-
trally located artery surrounded by a 4–6 mm thick zone of soft tissue composed of numerous peripheral nerves, 
mesenteric adipose tissue, and fibrovascular tissue. The coagulonecrotic tissue observed microscopically was 
located primarily in a layer on the surface of the treated portion of the artery and is likely a result of thermal 
necrosis associated with the thermal therapy applied to the artery (Fig. 5F). The coagulative necrosis appears to 
primarily affect the mesenteric adipose tissue resulting in saponification of the adipose tissue. There was coag-
ulative necrosis of a few isolated peripheral nerve bundles near the treated surface of the tissue surrounding the 
mesenteric artery. Importantly, there was no observed damage to the AMA in the center of the bundle of treated 
tissue and neither in the intestines (Fig. 5G and H).
Discussion
Vascular and in particular arterial invasion, is a key aspect in the resectability of a range of tumors, and therefore 
often dictates a patient’s prognosis and survival. Here, we describe the functionality of an innovative new device 
we have developed, named the CorleyWare device, to treat tumors with arterial involvement. The long-term goal 
of the device is to provide an intra-operative tool to deliver localized, mild and controlled hyperthermia to cancer 
margins that cannot be surgically resected due to them laying close to an unresectable vessel. We used PDAC 
www.nature.com/scientificreports/
8SCIEntIFIC REPORTS | 7: 11299  | DOI:10.1038/s41598-017-10508-6
as a model for our studies as it commonly associates with mesenteric vasculature during its local advancement. 
In vitro data suggests that mild hyperthermia, in the range of 46 °C for 10 minutes is an optimal thermal dose to 
Figure 4. Effect of the blood heat sink on CWD heating dynamics in the femoral artery in-vivo. (A) CWD 
placement around femoral artery with insertion of a fiber optic temperature probe inside artery and another 
probe on the artery surface (probe inserted in direction of blood flow to minimize turbulence in blood flow 
inside artery) (B) femoral artery after hyperthermia treatment (yellow arrows indicate areas where cauterization 
was performed to skeletonize branches from main vessel) (C) Heating differential between the outside femoral 
artery surface (black curve) and inside the femoral artery lumen (grey curve). (Red arrow indicates time-point 
when hyperthermia was halted) (D) Simulation of tissue heating using the CWD on a 1 mm positive cancer 
margin and (E) simulation of tissue heating using the CWD on a 10 mm positive cancer margin. The solid 
horizontal line indicates 46 °C, the desired tissue temperature. The vertical dotted lines are the innermost edge 
of the blood vessel wall, the vertical dashed line is the outermost edge of the tissue and the vertical dash-dot line 
is the interface between the blood vessel and the tissue. Tumor tissue thicknesses are: (A) 1 mm (B) 10 mm.
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induce high levels of cancer cell death when compared to non-malignant cells and eliminate the renewability 
function of CSCs. In vivo and in silico data supports the well-known phenomena of a blood heat sink that causes 
high temperature differentials through tissues undergoing hyperthermia. Additionally, the tissues themselves, 
especially tumor tissue, have high temperature differentials over relatively short distances representing common 
positive margins that may be due to the tissue characteristics such as the dense stromal reaction found in PDAC.
We believe hyperthermia treatment of the positive margin left on vessels such as the SMA during surgery 
in patients whose tumors are to date considered borderline or unresectable may allow a longer period of time 
between surgery and tumor recurrence, hence increasing patient recovery time before being able to commence 
chemotherapy regimens and improving the probability of achieving surgical result commensurate with curative 
intent. However, we acknowledge that this will need to be proven clinically in future trials.
Additionally, we propose that the heat differential provided by blood flow in the vessel will enable a protective 
effect for the inside lumen whilst the outside cancer layer is heated. This will mean that the outside cancer layer 
can possibly be exposed to higher thermal doses increasing kill efficacy during hyperthermia treatment. The 
effect of the blood heat sink may be further enhanced with the use of a localized blood cooling aid upstream of 
the device and/or a splanchnic vasodilator to increase arterial blood flow; however these were not tested herein. 
Previous device designs encased larger portions of the artery and we noticed that the slimmer design enabled the 
blood heat sink to be maintained for longer periods (Data not shown). We speculate this is due to the slim design 
of the later device meant that blood had a shorter distance to travel under hyperthermia and hence would not 
have a time to substantially increase in temperature and would therefore conserve the heat sink effect to a greater 
degree.
Our simulations of a simplified model of pancreatic tumor tissue surrounding a blood vessel predicted a large 
thermal differential through a relatively thin section of tissue. These large thermal differentials were validated by 
our in vivo and ex vivo experiments. Future simulations will be more sophisticated, including pulsed arterial flow, 
variable heart rate, and explicit simulation of blood flow. These simulations will provide an important tool for 
Figure 5. SMA Pathology after CWD treatment. Planar view of a femoral artery with corresponding zoomed 
in view of the endothelium (right). (A) Untreated femoral artery (B) femoral artery exposed to 46 °C for 
10 mins and (C) femoral artery exposed to 55 °C for 10 mins. (D) Scanning electron micrograph of the tunica 
intima of an untreated and (E) 46 °C for 10 mins treated tunica intima of the femoral artery (F) Adipose tissue 
surrounding the treated portion of the artery (G) Muscle wall and endothelial layer of the treated portion of the 
artery (H) Small intestine (right hand images are zoomed in images).
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the surgeon when deciding the thermal doses warranted for patients of different sizes and weights with varying 
positive margin thicknesses.
Lines of future exploration should involve techniques to increase the blood cooling effect by introducing a 
localized cooling aid such as a cooling pack (33 °C and 36 °C, as anything below 30 °C may introduce vasocon-
striction) upstream of the tissue undergoing hyperthermia, cooling the encased artery as the device is heating the 
outside cancer layer and thus hypothetically increase the heat differential between the cancer layer outer surface 
and the lumen of the vessel. The efficacy of the device may be improved by the incorporation of chemotherapeutic 
drugs into the inner surface of the device. Drugs can be delivered homogeneously on the tumor section encom-
passing the artery via the use of micro-needles or sponge delivery system, such as intercalated chemotherapeutics 
into various polymers such as PLA or biocompatible silk scaffolds. Finally, it is noteworthy that while the work 
herein used PDAC as a model cancer, we foresee this device being used to treat other cancers where resection is 
not accessible.
Methods
Ethic statement. All experiments were performed after approval of the Institutional Animal Care and 
Use Committee (IACUC) of Baylor Collage of Medicine (No. AN-6448 and AN-7062) and followed established 
protocols.
Cell lines. Human PDAC lines, PANC-1 and AsPc-1, cells were obtained from American Type Culture 
Collection (ATCC). PANC-1 and AsPc-1 cells were maintained in DMEM with 10% FBS. Human umbilical vein 
endothelial cells (HUVEC) (Lonza, Walkersville, MD, USA) were maintained in vascular cell basal medium sup-
plemented with 0.2% bovine brain extract, 5 ng/mL rh EGF, 10 mM L-glutamine, 0.75 units/mL heparin sulfate, 
1 µg/mL hydrocortisone hemisuccinate and 2% fetal bovine serum and 50 µg/mL ascorbic acid.
Human microvascular endothelial cells (HMVEC) (Lonza, Walkersville, MD, USA) were incubated in 
endothelial cell basal medium (Lonza) supplemented with endothelial cell growth medium (EGM) microvascular 
bullet kit containing 25 mL FCS, 0.5 mL hEGF, 0.5 mL hydrocortisone, 0.5 mL gentamicin, 0.5 mL bovine brain 
extract (Lonza). Cells were grown to confluence and when needed harvested with trypsin-EDTA (Lonza). All 
cells lines were maintained in a 95% humidified atmosphere of 5% CO2 at 37 °C and 2% penicillin-streptomycin 
solution was added to the media of all cell lines.
Human pancreatic stellate cells (PSCs) were provided by Dr. R. Hwang (UT-MD Anderson Cancer Center, 
Houston TX). Fresh tissue was obtained from residual PDAC specimens from patients undergoing primary sur-
gical resection at The University of Texas M. D. Anderson Cancer Center. Informed consent was granted for the 
harvesting of human tumor tissue samples to isolate pancreatic stellate cells. All human samples were obtained 
in accordance with the policies and practices of the Institutional Review Board of The University of Texas M. D. 
Anderson Cancer Center. The PSCs were isolated and prepared as previously described30 Briefly, PSCs were pre-
pared by the outgrowth method48. Fresh tissue was obtained from residual PDAC specimens from patients under-
going primary surgical resection at The University of Texas M. D. Anderson Cancer Center. All human samples 
were obtained in accordance with the policies and practices of the Institutional Review Board of The University 
of Texas M. D. Anderson Cancer Center. Tumor samples were minced and seeded in six-well plates containing 
15% FCS/DMEM, l-glutamine (2 mmol/L), penicillin/streptomycin, and amphotericin. Five days later, cells were 
able to grow out from the tissue clumps. When PSCs grew to confluence, cells were trypsinized and passaged at a 
1:3 ratio. Cell purity was determined by immunohistochemistry for alpha-SMA, vimentin, and desmin, as well as 
morphology (spindle-shaped cells with cytoplasmic extensions) and positive staining with Oil Red O (lipid inclu-
sions were visualized). Further, PSC derived from the pancreatic tumor of a patient who had received no prior 
therapy before surgery were immortalized using lentiviral vector with human telomerase (hTERT) or SV40 large 
T antigen (TAg) through plasmids containing TAg (pHIV7-CNPO-TAg) and hTERT (pHIV7-CNPO-hTERT) as 
previously described in details49. PSCs carrying the hTERT or SV40-T were selected in 1 to 3 mg/mL G418 for 3 
weeks (Invitrogen). Cells were maintained in DMEM with 10% FBS at 37 °C in a humidified atmosphere of 5% 
CO2.
In-vitro time-resolved cytotoxicity testing. Cytotoxicity was quantified using DNA-binding DRAQ7 
(Biostatus Ltd, UK) staining, which is a far-red fluorescent dye. Cells were seeded at a concentration of 100,000 
cells per well in Greiner Bio One Cellstar® tissue culture 6-well plate for 24 h. Plates were then placed into a water 
bath and heated to the given thermal dose. An optical probe was inserted into a cell free well that contained 2 ml 
of media so that accurate thermometry of the plate bottom could be achieved. After 10 mins of water bath hyper-
thermia, 3 µM concentration of DRAQ7 was placed in the cell medium before being gently pipetted to ensure 
thorough mixing. High throughput microscopy was performed within 10 min of adding the DRAQ7 using the 
ImageXpress Micro XL microscope (GE Healthcare, USA). Images were obtained which included 10,000 cells at 
0 h and 24 h time points in triplicate for statistically robust findings. Cells were imaged at 20x magnification in 
two wavelengths: the DRAQ7 (Cy5, Absorbance 600 nm emission 697 nm) and the bright-field wavelengths. At 
the end of the time-lapse experiment the cells were placed in 52 °C water for 10 minutes to induce 100% cell death 
before an additional set of images was collected, from which a measure of the total number of cells in each well 
was obtained. Cell death was quantified by the automated measure of the DRAQ7 signals at 0 and 24 h time points 
using MetaXpress 5.3.0.5 and MetaXpress PowerCore 1.3.0.3 software (Molecular Devices, USA).
Reverse-Phase Protein Array Assay. Reverse phase protein array (RPPA) assays were performed as 
described previously50, 51 with minor modifications. Protein lysates were prepared from the cell culture sam-
ples with Tissue Protein Extraction Reagent (TPER; Pierce) supplemented with 450 mM NaCl and a cocktail 
of protease and phosphatase inhibitors (Roche Life Science). Protein lysates at 0.5 mg/ml of total protein were 
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denatured in SDS sample buffer (Life Technologies) containing 2.5% 2-mercaptoethanol at 100 °C for 8 min. 
Protein lysates were arrayed onto nitrocellulose-coated slides (Grace Bio-labs, Bend, OR, USA) using an Aushon 
2470 Arrayer (Aushon BioSystems, Billerica, MA, USA) with an array format of 960 (experimental and controls) 
lysates per slide with each sample spotted as technical triplicates (2,880 spots per slide). Slides were blocked for 1 h 
with I-Block reagent (Applied Biosystems) followed by a 15 min incubation with Re-Blot reagent (Dako) and were 
loaded on an automated slide stainer Autolink 48 (Dako, Carpinteria, CA, USA) for incubation with primary 
antibodies. Antibody binding was detected by fluorescence with a Vectastain-ABC Streptavidin–Biotin Complex 
(Vector, PK-6100) followed by incubation with the TSA-plus Biotin Amp Reagent diluted at 1:250 (Perkin Elmer, 
NEL749B001KT) and a 1:50 dilution of LI-COR IRDye 680 Streptavidin (Odyssey) as the detection probe. The 
total protein content of each spotted lysate was assessed by fluorescent staining with Sypro Ruby Protein Blot 
Stain for selected subsets of slides (Molecular Probes). Fluorescent-labelled slides were scanned on a GenePix 
AL4400 scanner, and the images were analyzed with GenePix Pro 7.0 (Molecular Devices). For normalization, 
raw image intensity of each spot was subtracted from that of negative controls and then divided by total protein 
values. Tumors with different genetic backgrounds were analyzed separately. Of the 212 validated antibodies 
included in the RPPA, 143 antibodies detect total protein and 69 detect specific phosphorylated states known 
to be markers of protein activation. The validated antibodies represent proteins in various signaling pathways 
and cell functional groups including growth factor receptors, cell cycle, cell proliferation, apoptosis, EMT, stem 
cells, DNA damage, cell stress, autophagy, cytokines, protein translation and gene transcriptional activators and 
repressors. For a complete list of validated antibodies see https://www.bcm.edu/centers/cancer-center/research/
shared-resources/antibody-based-proteomics. Significantly differentiated antibodies between experimental 
groups were determined using a cutoff of P < 0.05 (by two-sided Student’s t-tests) and FC (fold change) > 1.25 
(or < 1/1.25).
Pancreatic cancer stem cell viability/renewability assays. Cells were seeded at a concentration of 
100,000 cells per well in Greiner Bio One Cellstar® tissue culture 6-well plate for 24 h. Plates were then placed 
into a water bath and heated to the target thermal dose. An optical probe was inserted into a cell free well that 
contained 2 ml of media so that accurate thermometry of the plate bottom could be achieved. After 10 mins of 
water bath hyperthermia, the media was collected and the cells were trypsanised before being added to the super-
natant media and spun down. For the tumor sphere-forming assay the cells were reseeded in six-well ultra-low 
attachment plates (Corning) with 2 mL of serum-free mammosphere medium. Fresh mammosphere medium was 
added to the wells every 3 days. The number of viable PDAC spheres at 14 days were imaged using ImageXpress 
Micro XL microscope (GE Healthcare, USA) and counted using MetaXpress 5.3.0.5 software (Molecular Devices, 
USA).
For the surface marker expression analysis, APC-labeled mouse anti-human CD44 (clone G44–26) and 
FITC-labeled mouse anti-human CD24 (clone mL5) were both purchased from BD Pharmingen (San Diego, CA). 
7-AAD Viability Staining Solution was purchased from eBioscience (San Diego, CA). PANC-1 cells were removed 
from flasks using Enzyme Free Cell Dissociation Buffer (ThermoFisher) and rinsed in FACs buffer (PBS + 2% 
FBS) prior to staining. Cells were then stained for surface antigens according to the antibody manufacturer’s 
instructions. Following the last rinse to remove any free antibody, cells were suspended in 200 µL PBS and 5 µL 
7-AAD viability stain was added 5–15 minutes prior to analysis on a Attune NXT flow cytometer (ThermoFisher). 
Analysis was performed using FlowJo version 10. Single color and unstained controls were used for proper gating 
and compensation.
Scanning electron microscopy (SEM). Cells were fixed by washing thrice with 0.1 M sodium cacodylate 
buffer (CDB) followed by incubation in 2.5% glutaraldehyde for 25 min at room temperature. Next, cells were 
washed twice in 0.1 M CDB and subjected to an ethanol series for dehydration. The cells were then incubated 
in 1:1 t-butanol:ethanol mixture for 5 min and mounted on carbon tape upon an SEM stub. Immediately before 
imaging the samples were sputter coated with 50% platinum 50% palladium at a thickness of 5.0 ± 0.2 nm to 
ensure good electrical conductivity.
Generation of orthotopic PDAC tumors in mice and hyperthermia administration. Animal stud-
ies were performed in accordance with the guidelines of the Animal Welfare Act and the Guide for the Care and 
Use of Laboratory Animals based on approved protocols by Baylor College of Medicine Institutional Animal 
Care and Use Committee (IACUC). Mice were kept in standard housing conditions and diet with free access to 
water. Orthotopic pancreatic tumors were grown in 6–7 week old athymic nude (FOXn1 nu) female mice (Harlan 
Sprague Dawley, USA). Under sterile conditions a 1cm  incision was made in the left flank to expose the pancreas. 
PANC-1 cells (1 × 106 in 40 µL of 1:1 PBS:Matrigel) were injected into the pancreas. The abdominal wound was 
closed in two layers. Tumors were allowed to grow for 6 weeks before being used for experimentation.
The CorleyWare device depicted in Figure S2A was used for ex vivo measurement of heating differentials and 
tumor damage due to hyperthermia. Tumor were excised from the mice after euthanization and then exposed to 
various thermal doses with optical temperature probes place on their surface and within their core before imme-
diate fixation in 4% formaldehyde for histology preparation. The experimental set up of the tumor, CWD and 
temperature probes is shown in Figure S5A and B.
The measurement of in vivo heat differential and tumor damage due to hypethermia involved non-survival 
surgery where under anesthesia the tumor was gently removed from the abdomen of the mouse before probes 
were positioned on the tumor surface and into the core of the tumor. Hyperthermia involving various target 
thermal doses was then administered. The CorleyWare device depicted in Figure S2A was used for ex vivo meas-
urement of heating differentials and tumor damage due to hyperthermia and the experimental set up involving 
the position of the tumor, mouse, temperature probes and CWD is shown in Fig. 3A and B. After the treatment, 
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the peritoneum and skin layers were gently closed and the mouse was kept sedated for two hours under anesthesia 
before being euthanized. The tumor was then excised and immediately fixed in 4% formaldehyde for histology 
preparation.
Large Animal Models. Female Yucatan miniature swine (Sinclair Bioresources; Auxvasse, MO) were housed 
and raised according to Institutional Animal Care and Use Committee (IACUC) guidelines at the Baylor College 
of Medicine. No special diet was given. At the time of Corleyware testing, pigs were 12 months of age and weighed 
70–75 kg.
For femoral artery heat differential measurements, a Yucatan miniature swine was sedated and anesthetized 
without complications for non-survival surgery. Their femoral artery was exposed for the delivery of a localized 
thermal treatment. Hyperthermia was administered using the CorleyWare device depicted in Figure S2A and the 
experimental set up involving the position of the artery, temperature probes and CWD is shown in Fig. 4A. All 
animals were stable throughout the procedure.
For survival surgery when investigating any delayed onset of pathology associated with hyperthermia admin-
istration to the SMA, a female Yucatan swine was sedated and anesthetized without complications. The SMA 
was exposed and further skeletonized before being given a localized thermal dose of 41 °C for 10 mins using the 
CWD depicted in Figure S2C. This version of the device is used in anatomical locations were space is minimal. 
The experimental set up involving the position of the SMA and the CWD is shown in Fig. 3A and B. Temperature 
probes were not needed during this procedure due to this version of the device possessing an in-built temperature 
sensing surface thermocouple. Pain medications (75 mcg/hr fentanyl patch and 0.4 mg/kg Meloxicam SQ) and 
peri-operative antibiotics were provided (1 gram Cefazolin IV). The animal stable throughout the procedure with 
1300 mL of IV LRS administered. A local anesthetic (5 mL lidocaine, 5 mL mL bupivacaine and 5 mL saline) was 
injected after closure. The swine was euthanized 48 h after the procedure, where a gross pathological assessment 
and a subsequent histological assessment of relevant tissues were performed.
Immunohistochemical evaluation. Tissue samples were fixed in formalin and processed in paraffin 
blocks and sectioned using standard techniques. Tissue slides were stained with H&E, Verhoeff-Van Gieson 
(Elastic fibers) and Cleaved PARP (apoptosis). Histology slides were imaged using Nikon Eclipse TE2000-U 
microscope fitted with a Nikon digital sight DS-Fi1 video camera. All slides were imaged at a fixed 167 ms expo-
sure time.
Computer simulation of CWD. Simple simulations of the Corleyware device were performed using the 
software Sim4Life (ZMT Zurich MedTech AG, Zurich, Switzerland)47. The model for all simulations consisted 
of a cylindrical blood vessel (inner diameter 4.5–7 mm, with 1 mm vessel walls), partially enclosed by a cylindri-
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where T is the temperature of the tissue of interest, t is time, ρ is the density, s is the specific heat, k is the thermal 
conductivity, and Qm is the rate of metabolic heat production for a specific tissue type. The constants ρbl, sbl, and 
wbl are the density, specific heat and perfusion rate of blood through the tissue, and Tbl is the temperature of blood. 
Note that the electric field heating term of the Pennes equation was omitted since it was not needed in this case. 
We also did not consider vasodilation of the artery in the simulation as during pig experiments we were treating 
a small portion of the artery (treated areas were ~3 cm in length) and no recordable vasodilative reaction of the 
artery were observed during surgery along with no decrease in heart rate due to decreased vascular resistance. 
Additionally, in mice experiments, core temperatures remained constant throughout the experiments and PDAC 
tumors were hypovascularized. Values for all physical constants were taken from the IT’IS Database for Thermal 
and Electromagnetic Parameters of Biological Tissues52. For all simulations, blood temperature was fixed at 37 °C 
and the background temperature was set to 25 °C. Flow of blood through the SMA was not explicitly modeled. 
Instead, blood flow was treated as constant, not pulsed, flow by the blood flow term of the Pennes equation:
ρ − .s w T T( ( )) (2)bl bl bl bl
The Pennes equation was also used for non-biological materials. If the blood perfusion and metabolic 
terms are set to zero, the Pennes equation is reduced to the three-dimensional heat equation53. Heating of the 
Corleyware device was achieved by using a non-zero rate of metabolic heat production (Qm), where the value of 
Qm was chosen to produce the desired temperature.
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